Distribution Agreements | “Next Purell” Opportunity
Listing Number: BBF-1248-00064 May Qualify For Visa

Business Overview

This is a rare opportunity to acquire a patented, FDA-focused medical products company positioned to disrupt the global hand sanitization industry. Developed by a visionary retired dentist, the company has created a breakthrough alcohol-free antimicrobial solution designed to deliver alcohol-level germ protection while being significantly gentler on skin.

After over a decade of formulation development and testing, the product line is positioned for full-scale commercialization with established pre-market approvals and distribution relationships in place.

Key Highlights
Proprietary patented alcohol-free antimicrobial technology
FDA-focused product pipeline nearing commercialization
60+ formulation iterations developed over 10+ years
Validated independent university study confirming effectiveness
Strong branding and trademarked product identity
Positioned as a potential disruptive alternative in a $3.6B global market
Product Innovation

The company’s flagship product is a scientifically developed, alcohol-free hand sanitizer that:

Provides antimicrobial protection comparable to alcohol-based sanitizers
Is designed to be gentle on skin with repeated use
Supports frequent sanitization without dryness or irritation
Utilizes a unique FDA-permitted active ingredient system

This innovation is designed to address long-standing concerns associated with alcohol-based sanitizers, including skin damage and safety concerns from prolonged exposure.

Market Position & Validation
Pre-market relationships established with major distributors:
McKesson Medical
Henry Schein
Medline
Retail approval channels include:
CVS
Walgreens
Target
Costco
Office Depot
Staples

The product is positioned for large-scale distribution pending final regulatory approval steps.

Intellectual Property & Assets
Patented antimicrobial formulation
Trademarked brand identity (“safeHands”)
Established product formulations and documentation
Distribution agreements and pre-approvals
Scientific validation studies and supporting research data
Growth Opportunity
FDA approval completion and commercialization rollout
Entry into global sanitization and healthcare markets
Expansion into institutional, school, hospital, and retail channels
Potential licensing or acquisition by major pharmaceutical or consumer health companies
Strong scalability across international markets
Financial Summary
Asking Price: $3,000,000
Gross Sales: $300,000
Seller’s Discretionary Earnings: $135,000
Down Payment: $3,000,000
Assets Included
Inventory: $175,000 (Included)
Furniture, Fixtures & Equipment: $5,000 (Included)
Total Assets: $180,000
Additional Financial Notes
Includes assumption of approximately $275K COVID-related loan
Includes approximately $300K additional structured debt (monthly payment plan)
Asset sale includes intellectual property, trademark, and distribution relationships
Facilities
Relocatable business model
No fixed real estate requirement
Designed for scalable manufacturing and outsourced production model
Business Details
Relocatable: No
Home-Based: No
Franchise: No
Lender Pre-Qualified: No
Visa Qualified: Yes
Location
County: Palm Beach
State: Florida
Country: USA
Detailed Description

This is a breakthrough medical products opportunity featuring a patented alcohol-free antimicrobial hand sanitizer positioned to redefine the global hygiene market. Developed by a retired dental professional with a history of innovation in medical dispensing technology, the product addresses key limitations of alcohol-based sanitizers by offering effective germ protection without skin damage.

Supported by independent scientific validation and pre-market distribution agreements with major healthcare and retail organizations, the company is strategically positioned for commercialization pending FDA approval. With strong intellectual property, established branding, and a large addressable global market, this represents a high-impact opportunity for a strategic investor or industry acquirer seeking to scale a disruptive healthcare innovation.